DPP-4 Inhibition and the Path to Clinical Proof.

Volume: 10, Pages: 376 - 376
Published: Jun 19, 2019
Abstract
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibition results in raised levels of the two incretin hormones which in turn result in lowering of circulating glucose through stimulation of insulin secretion and inhibition of glucagon secretion. Since then, several small orally available...
Paper Details
Title
DPP-4 Inhibition and the Path to Clinical Proof.
Published Date
Jun 19, 2019
Volume
10
Pages
376 - 376
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.